Enhancement parameters of contrast-enhanced computed tomography for pancreatic ductal adenocarcinoma: Correlation with pathologic grading

Table 3 Differences in computed tomography parameters among the well-differentiated, moderately differentiated, and poorly differentiated group groups

	WD (n = 13)	MD (n = 21)	PD (n = 8)	P value
VTarterial	69.01 ± 25.16 (64.22)	75.23 ± 19.69 (75.41)	59.80 ± 29.47 (56.30)	0.145
VTpancreatic	85.34 ± 23.20 (76.08)	90.58 ± 21.99 (90.58)	73.19 ± 39.88 (69.01)	0.184
VAarterial	280.71 ± 66.66 (262.74)	290.37 ± 61.12 (279.38)	320.04 ± 86.26 (311.20)	0.496
VApancreatic	201.73 ± 55.81 (200.00)	200.85 ± 43.82 (209.44)	188.28 ± 46.94 (195.43)	0.683
DT	16.32 ± 6.48 (13.65)	15.34 ± 8.06 (13.97)	13.39 ± 13.25 (10.16)	0.678
DA	78.98 ± 49.68 (61.54)	89.51 ± 34.84 (91.01)	131.76 ± 58.68 (120.79)	0.077
TARarterial	0.26 ± 0.12 (0.23)	0.27 ± 0.09 (0.25)	0.19 ± 0.07 (0.20)	0.164
TARpancreatic	0.45 ± 0.16 (0.36)	0.48 ± 0.17 (0.47)	0.37 ± 0.12 (0.38)	0.339
TAF	0.28 ± 0.24 (0.19)	0.19 ± 0.12 (0.17)	0.10 ± 0.08 (0.10)	0.034

Data are presented as mean ± SD (median). WD: Well-differentiated; MD: Moderately differentiated group; PD: Poorly differentiated group; VT_arterial and VT_pancreatic: Attenuation value of the tumor in the arterial and pancreatic phases, respectively; VA_arterial and VA_pancreatic: Attenuation value of the aorta in the arterial and pancreatic phases, respectively; DT and DA: Degree of tumor enhancement and aortic washout between the arterial and pancreatic phases, respectively; TAR_arterial and TAR_pancreatic: Tumor-to-aorta enhancement ratio in arterial and pancreatic phases, respectively; TAF: Tumor-to-aortic enhancement fraction.